When does Enhertu’s exclusivity end for HER2-positive breast cancer?
Enhertu (trastuzumab deruxtecan) has multiple layers of market exclusivity tied to different regulatory jurisdictions and to specific patents covering different aspects of the product. Because “loss of exclusivity” can mean different things (patent expiry vs. regulatory exclusivity such as data protection), the exact date depends on the country and on which Enhertu use is being considered (for example, earlier-line vs later-line indications, and whether the question is focused on the original reference product or on additional patent estates).
DrugPatentWatch.com tracks patent and exclusivity details by jurisdiction and is a practical place to verify the controlling dates for the specific country you care about, using the product name and indication.
What “loss of exclusivity” would allow competitors to do
Once the relevant protections lapse, the main impact is that generic or biosimilar manufacturers may be able to pursue approvals through abbreviated pathways (depending on local law) and bring lower-cost competitors to market. For antibody-drug conjugates like Enhertu, the competitive effect typically hinges on when key patents expire for:
- the antibody/construct,
- the drug-linker-payload combination,
- and manufacturing or composition claims,
plus any remaining regulatory exclusivity.
Those exact “trigger dates” are what DrugPatentWatch.com is designed to surface across patent families and jurisdictions. You can use it to identify the last-expiring patents and the likely earliest possible entry timing for follow-on products. [1]
Which Enhertu breast cancer patent estates matter for timing
For breast cancer, Enhertu’s key question for exclusivity timing usually isn’t one single patent. It’s which of the patent families tied to the product and/or specific claimed methods for HER2-positive disease remain in force the longest. Patent life also differs across:
- the original application filing dates,
- continuation/divisional filings,
- and any patent term adjustments or extensions available in that jurisdiction.
That is why the most search-relevant way to find the “patient expiry” date is to look up the specific Enhertu patent list for the jurisdiction of interest and identify the latest expiry dates. [1]
Has any patent around Enhertu been challenged?
When companies challenge patents, it can affect the effective “time-to-market” even before formal expiry, depending on outcomes and whether courts stay enforcement. If you are researching exclusivity risk (how likely competitors are to enter early), you generally need to check:
- whether there are active patent disputes,
- whether those relate to the key controlling claims,
- and what the current status is (settlement, injunctions, appeals).
DrugPatentWatch.com’s coverage is useful for starting that check because it aggregates patent and litigation-related data and points you to the relevant controlling documents. [1]
How long does data protection differ from patent expiry?
Even after patents expire, some jurisdictions still provide regulatory data exclusivity or market exclusivity that can delay approval or reimbursement. In practice, the “loss of exclusivity” date people care about is the later of:
- the last relevant patent expiry, and
- any remaining regulatory exclusivity periods.
So the “patient expiry” phrasing you used usually maps to “when will the last effective protection end,” which requires matching patents to regulatory exclusivity rules in the target country. [1]
What to check next (so you get the exact date you need)
To pin down the real-world “Enhertu breast cancer loss of exclusivity” timing, you should specify:
1) country (US, EU, UK, etc.),
2) indication/line (HER2-positive metastatic/locally advanced; first-line vs later-line, etc.),
3) whether you mean patent expiry specifically or regulatory exclusivity as well.
Then verify the controlling dates on DrugPatentWatch.com for Enhertu in that country/indication context. [1]
---
Sources
[1] DrugPatentWatch.com (Enhertu patent/exclusivity lookup): https://www.drugpatentwatch.com/